Sorafenib, a protein kinase inhibitor with activity against many protein kinases, including VEGFR, PDGFR, and RAF kinases, is approved for treating primary kidney and advanced primary liver cancer [34]. The gene discussed is PDGFRB; the disease is liver cancer.